Literature DB >> 2953072

D1 dopamine receptor activation required for postsynaptic expression of D2 agonist effects.

J R Walters, D A Bergstrom, J H Carlson, T N Chase, A R Braun.   

Abstract

D1 and D2 dopamine receptors exert synergistic effects on the firing rates of basal ganglia neurons and on the expression of stereotyped behavior in rats. Moreover, the ability of D2 agonists to induce changes in basal ganglia single unit activity and spontaneous motor activity is dependent upon the presence of endogenous dopamine to stimulate D1 receptors; in rats treated with alpha-methyl-rho-tyrosine to reduce endogenous dopamine levels, the neurophysiological and behavioral effects of the D2 agonist quinpirole are significantly attenuated, while the effects of nonselective agonists like apomorphine, which stimulate both D1 and D2 receptors, or combinations of a D2 agonist and a D1 agonist are not attenuated. Thus, the previously held view that D2 receptors alone are responsible for evoking the changes in behavior and basal ganglia output induced by nonselective dopamine agonists and endogenous dopamine is not supported by these results, which indicate that these phenomena require concurrent stimulation of both dopamine receptor subtypes.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2953072     DOI: 10.1126/science.2953072

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  66 in total

1.  Effects of prenatal exposure to methylmercury on dopamine-mediated locomotor activity and dopamine D2 receptor binding.

Authors:  Elisabetta Daré; Serguei Fetissov; Tomas Hökfelt; Håkan Hall; Sven Ove Ogren; Sandra Ceccatelli
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-04-09       Impact factor: 3.000

Review 2.  From reinforcement learning models to psychiatric and neurological disorders.

Authors:  Tiago V Maia; Michael J Frank
Journal:  Nat Neurosci       Date:  2011-02       Impact factor: 24.884

Review 3.  Understanding antipsychotic "atypicality": a clinical and pharmacological moving target.

Authors:  Gary Remington
Journal:  J Psychiatry Neurosci       Date:  2003-07       Impact factor: 6.186

4.  Ontogenetic differences in the psychopharmacological responses to separate and combined stimulation of D1 and D2 dopamine receptors during the neonatal to weanling age period.

Authors:  C A Moody; L P Spear
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

5.  Repetitive behaviors in monkeys are linked to specific striatal activation patterns.

Authors:  Esen Saka; Claudia Goodrich; Patricia Harlan; Bertha K Madras; Ann M Graybiel
Journal:  J Neurosci       Date:  2004-08-25       Impact factor: 6.167

6.  Dopaminergic control of locomotion, mouthing, snout contact, and grooming: opposing roles of D1 and D2 receptors.

Authors:  D Eilam; H Talangbayan; G Canaran; H Szechtman
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

7.  CART peptide inhibits locomotor activity induced by simultaneous stimulation of D1 and D2 receptors, but not by stimulation of individual dopamine receptors.

Authors:  Mark C Moffett; Jane Song; Michael J Kuhar
Journal:  Synapse       Date:  2011-01       Impact factor: 2.562

Review 8.  The external globus pallidus: progress and perspectives.

Authors:  Daniel J Hegeman; Ellie S Hong; Vivian M Hernández; C Savio Chan
Journal:  Eur J Neurosci       Date:  2016-03-28       Impact factor: 3.386

9.  Potentiation by low doses of selected neuroleptics of food-induced conditioned place preference in rats.

Authors:  A Guyon; F Assouly-Besse; G Biala; A J Puech; M H Thiébot
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

10.  Developmental Deltamethrin Exposure Causes Persistent Changes in Dopaminergic Gene Expression, Neurochemistry, and Locomotor Activity in Zebrafish.

Authors:  Tiffany S Kung; Jason R Richardson; Keith R Cooper; Lori A White
Journal:  Toxicol Sci       Date:  2015-04-24       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.